The DOI matches its Crossref record; 65 of the 72 references it cites were found in a registry or an index.
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53
Open accessAbstract
The INK4a gene encodes two distinct growth inhibitors--the cyclin-dependent kinase inhibitor p16Ink4a, which is a component of the Rb pathway, and the tumor suppressor p19Arf, which has been functionally linked to p53. Here we show that p19Arf potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoproteins and dominant-negative mutants but not by the p53 antagonist MDM2. This finding, coupled with the observations that p19Arf and MDM2 physically interact and that p19Rrf blocks MDM2-induced p53 degradation and transactivational silencing, suggests that p19Arf functions mechanistically to prevent MDM2's neutralization of p53. Together, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of its two protein products and their relation to the two central growth control pathways, Rb and p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p19 Arf has been shown to inhibit Mdm2-mediated degradation of p53 (19-21) and is clearly required for activation of p53 in response to aberrant cell cycle entry (19) and oncogene activation (22-24).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [19]
In the citing paper
“Under most conditions ARF functions as a tumor suppressor by binding and inhibiting Mdm2 activity [47–49].”
From Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis (2012) · cites this paper as [48]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,674
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
The p53 tumour suppressor gene
Levine, A. J., Momand, J. A., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,785
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Research works printed but not linked: 6
- Brenner, 1996, Preferential loss of expression of p16INK4a rather than p19ARF in breast cancer, Clin. Cancer Res., 2, 1993
- Elledge, 1996, A question of balance, Trends Biochem. Sci., 6, 388
- Kinoshita, 1996, Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer, Cancer Res., 56, 5557
- Quelle, 1995, Cloning and characterization of murine p16INK4a and p15INK4b genes, Oncogene, 11, 635
- Schreiber-Agus, 1994, Evolutionary relationships and functional conservation among vertebrate Max-associated proteins, Oncogene, 9, 3167
- Schreiber-Agus, 1997, An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3, Cell, 80, 777, 10.1016/0092-8674(95)90356-9 · DOI
Cited by
Sorted by citations
Items 501–600 of 1,001
Gewirtz, D. A. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006414422919 · Cited by 78
p53-related pathways and the molecular pathogenesis of melanoma
Hussein, M. R., Haemel, A. K., & Wood, G. S. (2003) · European Journal of Cancer Prevention · doi:10.1097/00008469-200304000-00002 · Cited by 78
Developmental defects and tumor predisposition in Rb mutant mice
Vooijs, M., & Berns, A. J. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202999 · Cited by 77
Wang, Y.-C., Lin, R.-K., Tan, Y. C., Chen, J.-T., Chen, C., & Wang, Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.139 · Cited by 77
Maloney, K. W., McGavran, L., Odom, L. F., & Hunger, S. P. (1999) · Blood · doi:10.1182/blood.v93.7.2380 · Cited by 77
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
Bertoni, F., Codegoni, A. M., Furlan, D., Tibiletti, M. G., Capella, C., & Broggini, M. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199910)26:2 · Cited by 132
Genetic Progression of Pancreatic Cancer
Cowan, R. W., & Maitra, A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000011 · Cited by 76
What have animal models taught us about the p53 pathway?
Lozano, G., & Zambetti, G. P. (2005) · The Journal of Pathology · doi:10.1002/path.1704 · Cited by 78
Immunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus
Lindström, M. S., Klangby, U., Inoue, R., Pisa, P., Wiman, K. G., & Asker, C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4854 · Cited by 77
Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis
Lessard, J. A., & Sauvageau, G. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00081-x · Cited by 76
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 80
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
Jackson, M. W., Lindström, M. S., & Berberich, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010685200 · Cited by 74
p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition
Ji, Z., Njauw, C.-N. J., Taylor, M., Neel, V., Flaherty, K. T., & Tsao, H. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.313 · Cited by 74
Petronzelli, F., Sollima, D., Coppola, G., Martini‐Neri, M. E., Neri, G., & Genuardi, M. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1159 · Cited by 74
Sdek, P., Ying, H., Zheng, H., Margulis, A. R., Tang, X., Tian, K., & Xiao, Z. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406062200 · Cited by 74
Human p14ARF-mediated cell cycle arrest strictly depends on intact p53 signaling pathways
Weber, H. O., Samuel, T., Rauch, P., & Funk, J. O. (2002) · Oncogene · doi:10.1038/sj.onc.1205429 · Cited by 74
RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
Saporita, A. J., Chang, H., Winkeler, C. L., Apicelli, A. J., Kladney, R. D., Wang, J., Townsend, R. R., Michel, L. S., & Weber, J. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1472 · Cited by 74
Itch/AIP4 Associates with and Promotes p63 Protein Degradation
Rossi, M., Simone, M. C. D., Pollice, A., Santoro, R., Mantia, G. L., Guerrini, L., & Calabrò, V. (2006) · Cell Cycle · doi:10.4161/cc.5.16.2861 · Cited by 74
Obligate Roles for p16 Ink4a and p19 Arf -p53 in the Suppression of Murine Pancreatic Neoplasia
Bardeesy, N. M., Morgan, J. A., Sinha, M., Signoretti, S., Srivastava, S., Loda, M. F., Merlino, G. T., & DePinho, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.635-643.2002 · Cited by 74
Self-citationQi, C., Mårtensson, A., Mattioli, M., Dalla‐Favera, R., Lobanenkov, V. V., & Morse, H. C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237127100 · Cited by 73
RNA content in the nucleolus alters p53 acetylation via MYBBP1A
Kuroda, T., Murayama, A., Katagiri, N., Ohta, Y., Fujita, E., Masumoto, H., Ema, M., Takahashi, S., Kimura, K., & Yanagisawa, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.23 · Cited by 77
Lee, S., Tarn, C., Wang, W., Chen, S., Hullinger, R. L., & ANDRISANI, O. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108025200 · Cited by 73
Aberrant ubiquitin-mediatedproteolysis of cell cycle regulatory proteins and oncogenesis
Bashir, T., & Pagano, M. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)88305-7 · Cited by 73
Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas
Newcomb, E. W., Alonso, M., Sung, T., & Miller, D. C. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80207-5 · Cited by 73
Progress in cancer genetics: Lessons from pancreatic cancer
Goggins, M., Kern, S. E., Offerhaus, J. G. A., & Hruban, R. H. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s4 · Cited by 75
CDKN2a/p16INK4a Mutations and Lack of p19ARF Involvement in Familial Melanoma Kindreds
Fargnoli, M. C., Chimenti, S., Peris, K., Keller, G., Soyer, H. P., Pozzo, V. D., & Höfler, H. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00412.x · Cited by 73
Beyond effector caspase inhibition
Stegh, A. H., & DePinho, R. A. (2011) · Cell Cycle · doi:10.4161/cc.10.1.14365 · Cited by 72
Self-citationTelomerase expression in lung preneoplasia and neoplasia
Lantuéjoul, S., Salon, C., Soria, J., & Brambilla, E. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22473 · Cited by 78
Castillo, J., Frame, F. M., Rogoff, H. A., Pickering, M., Yurochko, A. D., & Kowalik, T. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11467-11475.2005 · Cited by 72
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 72
Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma
Yang, G., Rajadurai, A., & Tsao, H. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23931.x · Cited by 71
DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer
Gjerset, R. A. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9040-y · Cited by 71
Edwards, S. J., Dix, B. R., Myers, C. J., Dobson-Le, D., Huschtscha, L. I., Hibma, M. H., Royds, J. A., & Braithwaite, A. W. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12483-12490.2002 · Cited by 71
Replicating Adenoviruses in Cancer Therapy
Dobbelstein, M. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05599-1_9 · Cited by 71
p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 71
ARF Differentially Modulates Apoptosis Induced by E2F1 and Myc
Russell, J. L., Powers, J. T., Rounbehler, R. J., Rogers, P. M., Conti, C. J., & Johnson, D. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.5.1360-1368.2002 · Cited by 72
P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3
Zerrouqi, A., Pyrzynska, B., Febbraio, M., Brat, D. J., & Van Meir, E. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci38596 · Cited by 70
Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy
Zhang, Z., Cheng, L., Li, J., Qiao, Q., Karki, A., Allison, D. B., Shaker, N., Li, K., Utturkar, S. M., Lanman, N. A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0018 · Cited by 70
p53 gene status and expression of p53, MDM2, and p14ARF proteins in ameloblastomas
Kumamoto, H., Izutsu, T., Ohki, K., Takahashi, N., & Ooya, K. (2004) · Journal of Oral Pathology and Medicine · doi:10.1111/j.0904-2512.2004.00044.x · Cited by 70
MECHANISMS OF AFLATOXIN B1LUNG TUMORIGENESIS
Thomas E. Massey, G. B. J. S. (2000) · Experimental Lung Research · doi:10.1080/01902140150216756 · Cited by 70
Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
Knocke, S., Fleischmann-Mundt, B., Saborowski, M., Manns, M. P., Kühnel, F., Wirth, T. C., & Woller, N. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.086 · Cited by 71
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 71
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70
pRb and E2f-1 in mouse development and tumorigenesis
Macleod, K. F. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80005-7 · Cited by 70
ARF tumor suppression in the nucleolus
Maggi, L. B., Winkeler, C. L., Miceli, A. P., Apicelli, A. J., Brady, S. N., Kuchenreuther, M., & Weber, J. D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.01.016 · Cited by 73
Carrasco, D. R., Fenton, T. R., Sukhdeo, K., Protopopova, M., Enos, M., You, M. J., Divicio, D., Nogueira, C., Stommel, J. M., Pinkus, G. S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.028 · Cited by 69
Self-citationInhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B. L., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 72
Genetic alterations and biological pathways in human bladder cancer pathogenesis
Reznikoff, C. A., Sarkar, S., Jülicher, K., Burger, M. S., Puthenveettil, J. A., Jarrard, D. F., & Newton, M. A. (2000) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(00)00079-x · Cited by 69
p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
Yang, C., You, L., Uematsu, K., Yeh, C., McCormick, F. P., & Jablons, D. M. (2001) · PubMed · Cited by 69
Alterations of INK4A and INK4B Genes in Adult Soft Tissue Sarcomas: Effect on Survival
Orlow, I., Drobnjak, M., Zhang, Z., Lewis, J., Woodruff, J. M., Brennan, M. F., & Cordon‐Cardo, C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.73 · Cited by 69
Self-citationSmall Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
Frank, A. J., Hernán, R., Hollander, A. B., Lindsey, J. C., Lusher, M. E., Fuller, C. E., Clifford, S. C., & Gilbertson, R. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.016 · Cited by 68
Macrophages, Inflammation, and Tumor Suppressors: ARF, a New Player in the Game
Través, P. G., Luque, A., & Hortelano, S. (2012) · Mediators of Inflammation · doi:10.1155/2012/568783 · Cited by 71
Lassacher, A., Heitzer, E., Kerl, H., & Wolf, P. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701256 · Cited by 69
Molecular classification and molecular genetics of human lung cancers
Meyerson, M. M., Franklin, W. A., & Kelley, M. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.009 · Cited by 68
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Dunne, R. F., & Hezel, A. F. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.003 · Cited by 68
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 69
ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress
Pauklin, S., Kristjuhan, A., Maimets, T., & Jaks, V. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.097 · Cited by 69
p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer
Summersgill, K. F., Smith, E., Kirchner, H. L., Haugen, T. H., & Turek, L. P. (2000) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1067/moe.2000.107359 · Cited by 67
Differentiation-Related Changes in the Cell Cycle Traverse
Studzinski, G. P., & Harrison, L. E. (1999) · International review of cytology · doi:10.1016/s0074-7696(08)61384-4 · Cited by 67
High‐density methylation of p14ARF and p16INK4A in Epstein‐Barr virus–associated gastric carcinoma
Sakuma, K., Chong, J., Sudo, M., Ushiku, T., Inoue, Y., Shibahara, J., Uozaki, H., Nagai, H., & Fukayama, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20420 · Cited by 66
Oncolytic Replication of E1b-Deleted Adenoviruses
Cheng, P.-H., Wechman, S. L., McMasters, K. M., & Zhou, H. (2015) · Viruses · doi:10.3390/v7112905 · Cited by 67
DNA Hypermethylation Status of Multiple Genes in Prostate Adenocarcinomas
Konishi, N., Nakamura, M., Kishi, M., Nishimine, M., Ishida, E., & Shimada, K. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01318.x · Cited by 66
Combined analysis of p53 and RB pathways in epithelial ovarian cancer
Hashiguchi, Y., Tsuda, H., Yamamoto, K., Inoue, T., Ishiko, O., & Ogita, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.27115 · Cited by 67
Activation of an MDM2-specific Caspase by p53 in the Absence of Apoptosis
Pochampally, R. R., Fodera, B., Chen, L., Lu, W., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15271 · Cited by 66
Labuhn, M., Jones, G., Speel, E. M., Maier, D., Zweifel, C., Gratzl, O., Meir, E. G. V., Hegi, M. E., & Merlo, A. U. (2001) · Oncogene · doi:10.1038/sj.onc.1204197 · Cited by 66
New and unexpected: forkhead meets ARF
Costa, R. H., Kalinichenko, V. V., Major, M. L., & Raychaudhuri, P. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.007 · Cited by 65
Head and neck cancer: Response to p53‐based therapeutics
Nemunaitis, J., & Nemunaitis, J. J. (2010) · Head & Neck · doi:10.1002/hed.21364 · Cited by 65
Genetic and Epigenetic Alterations in Tumor Progression in a Dedifferentiated Chondrosarcoma
Röpke, M., Boltze, C., Neumann, H., Roessner, A., & Schneider‐Stock, R. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00443 · Cited by 65
Heritability of cervical tumours
Magnusson, P. K. E., Lichtenstein, P., & Gyllensten, U. B. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001201)88:5 · Cited by 179
Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma
Ohta, S., Uemura, H., Matsui, Y., Ishiguro, H., Fujinami, K., Kondo, K., Miyamoto, H., Yazawa, T., Danenberg, K. D., Danenberg, P. V., et al. (2008) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2008.08.027 · Cited by 64
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 66
Association of p14ARF with the p120E4FTranscriptional Repressor Enhances Cell Cycle Inhibition
Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T. M., Rooney, R. J., & Kefford, R. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210978200 · Cited by 64
de Toledo, S. M., Azzam, E. I., Dahlberg, W. K., Gooding, T. B., & Little, J. B. (2000) · Oncogene · doi:10.1038/sj.onc.1204020 · Cited by 64
Cytokine response gene 6 induces p21 and regulates both cell growth and arrest
Fan, W., Richter, G. H. S., Cereseto, A., Beadling, C., & Smith, K. A. (1999) · Oncogene · doi:10.1038/sj.onc.1203054 · Cited by 64
Møller, M. B., Kania, P., Ino, Y., Gerdes, A., Nielsen, O., Louis, D., Skjødt, K., & Pedersen, N. (2000) · Leukemia · doi:10.1038/sj.leu.2401761 · Cited by 64
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 66
Olausson, K. H., Nistér, M., & Lindström, M. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.569244 · Cited by 64
Modulation of apoptosis by early human papillomavirus proteins in cervical cancer
Lagunas-Martínez, A., Madrid‐Marina, V., & Gariglio, P. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.005 · Cited by 67
Molecular pathways in bladder cancer
Williams, S. G., & Stein, J. P. (2004) · Urological Research · doi:10.1007/s00240-003-0345-y · Cited by 63
MUTATION OF CELL CYCLE REGULATORS AND THEIR IMPACT ON SUPERFICIAL BLADDER CANCER
Rabbani, F., & Cordon-Cardo, C. (2000) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70237-8 · Cited by 63
Self-citationp16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma
Vinci, A. D., Perdelli, L., Banelli, B., Salvi, S., Casciano, I., Gelvi, I., Allemanni, G., Margallo, E., Gatteschi, B., & Romani, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20771 · Cited by 63
Perugini, R. A., McDade, T. P., Vittimberga, F. J., Duffy, A. J., & Callery, M. P. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80029-3 · Cited by 63
Differential Regulation of E2F1, DP1, and the E2F1/DP1 Complex by ARF
Datta, A., Nag, A., & Raychaudhuri, P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8398-8408.2002 · Cited by 63
ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos
Tsai, K. Y., MacPherson, D. P., Rubinson, D. A., Crowley, D. G., & Jacks, T. (2002) · Current Biology · doi:10.1016/s0960-9822(01)00659-5 · Cited by 63
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression
Ming, Z., Lim, S. Y., & Rizos, H. (2020) · Biomolecules · doi:10.3390/biom10101447 · Cited by 65
Control of Human PIRH2 Protein Stability
Logan, I. R., Sapountzi, V., Gaughan, L., Neal, D. E., & Robson, C. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312712200 · Cited by 62
Essential Role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability
Enomoto, T., Lindström, M. S., Jin, A., Ke, H., & Zhang, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602788200 · Cited by 62
Sánchez‐Aguilera, A., Sánchez‐Beato, M., García, J. F., Priéto, I., Pollán, M., & Piris, M. A. (2002) · Blood · doi:10.1182/blood.v99.4.1411 · Cited by 62
Buschmann, T., Adler, V., Matusevich, E., Fuchs, S. Y., & Ronai, Z. A. (2000) · PubMed · Cited by 62
Association Between INK4a-ARF and p53 Mutations in Skin Carcinomas of Xeroderma Pigmentosum Patients
Soufir, N. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.22.1841 · Cited by 62
Mason, S., Loughran, Ö., & Thangue, N. B. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205524 · Cited by 62
Węsierska‐Gądek, J., & Schmid, G. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010101)80:1 · Cited by 62
CDKN2A Germline Mutations in Individuals with Cutaneous Malignant Melanoma
Orlow, I., Begg, C. B., Cotignola, J., Roy, P., Hummer, A., Clas, B. A., Mujumdar, U., Canchola, R., Armstrong, B. K., Kricker, A., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700689 · Cited by 61
Self-citationChaudru, V., Laud, K., Avril, M., Minière, A., Chompret, A., Paillerets, B. B., Démenais, F., & The French Familial Melanoma Study Group (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0777 · Cited by 61
E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cellsPreprint
Chagraoui, J., Niessen, S. L., Lessard, J. A., Girard, S., Coulombe, P., Sauvageau, M., Meloche, S., & Sauvageau, G. (2006) · Genes & Development · doi:10.1101/gad.1453406 · Cited by 62
Kadekaro, A. L. (2006) · Frontiers in bioscience · doi:10.2741/1958 · Cited by 60
p16INK4a‐induced senescence is disabled by melanoma‐associated mutations
Haferkamp, S., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00422.x · Cited by 66
ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
Wang, Y., Godin-Heymann, N., WANG, X.-D., Bergamaschi, D., Llanos, S., & Lü, X. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.3 · Cited by 60
Metadata
- Authors
- Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., Cordon-Cardo, C., & DePinho, R. A.
- Affiliations
- Albert Einstein College of Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- DePinho, Ronald A
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1998-03
- Volume
- 92
- Issue
- 6
- Pages
- 713-723
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2039463309
- Cited by
- 1,521
- References
- 72
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 23 · 2022: 19 · 2021: 23 · 2020: 19 · 2019: 16 · 2018: 12 · 2017: 24 · 2016: 27 · 2015: 32 · 2014: 44 · 2013: 44 · 2012: 47
- FWCI
- 64.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 47179, CA 47538, CADK97650, P01CA047179)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p19ARF, INK4A, MDM2, p53, tumor suppression, protein-protein interaction, p53 degradation, p53 transactivation, oncogenic transformation, Rb pathway, viral oncoproteins, dominant-negative mutant
- MeSH terms
- Animals, Biotin, Cell Line, Deoxyuracil Nucleotides, Lens, Crystalline, Neoplasm Proteins, Nuclear Proteins, Osteoblasts, Proteins, Proto-Oncogene Proteins, Staining and Labeling, Transformation, Genetic, Tumor Suppressor Protein p53, Retinoblastoma Protein, Apoptosis, Genes, p16, Tumor Suppressor Protein p14ARF, Mice, Proto-Oncogene Proteins c-mdm2, DNA Fragmentation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
